Retroviral gene transfer of dominant negative Raf-1 mutants suppresses Ha-ras-induced transformation and delays tumor formation

Cancer Gene Therapy

Volumn 7, Issue 5, 2000, Pages 697-706

  Heinicke, Thomas ^a   Radziwill, Gerald ^a   Nawrath, Michael ^a   Rommel, Christian ^a   Pavlovic, Jovan ^a   Moelling, Karin ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Dominant negative mutants; Ras transformation; Retroviral gene transfer

Indexed keywords

DNA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; GENE MUTATION; GENE TRANSFER; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; RETROVIRUS; TUMOR CELL;

ANIMALIA; MUS MUSCULUS; UNIDENTIFIED RETROVIRUS;

EID: 0034028730     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700155     Document Type: Article

References (44)

1. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
2. Moelling K, Heimann B, Beimling P, Rapp UR, Sander T. Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature. 1984;312: 558-561.
3. Morrison DK, Cutler RE Jr. The complexity of Raf-1 regulation. Curr Opin Cell Biol. 1997;9:174-179.
4. Aitken A. 14-3-3 proteins on the MAP. Trends Biochem Sci. 1995;20:95-97.
5. Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996;84:889-897.
6. Rommel C, Radziwill G, Lovric J, et al. Activated Ras displaces 14-3-3 from the amino terminus of c-Raf-1. Oncogene. 1996;12:609-619.
7. Rommel C, Radziwill G, Moelling K, Hafen E. Negative regulation of Raf activity by binding of 14-3-3 to the amino terminus of Raf in vivo. Mech Dev. 1997;64:95-105.
8. Avruch J, Zhang X, Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway Trends Biochem Sci. 1994;19:279-283.
9. Marais R, Marshall CJ. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv. 1996;27:101-125.
10. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9:726-735.
11. Zimmermann S, Rommel C, Ziogas A, Lovric J, Moelling K, Radziwill G. MEK1 mediates a positive feedback on Raf-1 activity independently of Ras and Src. Oncogene. 1997;15:1503-1511.
12. Waters SB, Yamauchi K, Pessin JE. Insulin-stimulated disassociation of the SOS-Grb2 complex. Mol Cell Biol. 1995;15:2791-2799.
13. ras desensitization by insulin. J Biol Chem. 1995;270: 1485-1488.
14. Hall A. A biochemical function for ras-at last. Science. 1994;264:1413-1414.
15. White MA, Nicolette C, Minden A, et al. Multiple Ras functions can contribute to mammalian cell transformation. Cell 1995;80:533-541.
16. Symsons M. Rho family GTPases: the cytoskeleton and beyond. Trends Biochem Sci. 1996;21:178-181.
17. Ogiso Y, Sakai N, Watari H, Yokoyama T, Kuzumaki N. Suppression of various human tumor cell lines by a dominant negative H-ras mutant. Gene Ther. 1994;1:403-407.
18. Howe LR, Leevers SJ, Gomez N, Nakielny S, Cohen P, Marshall C. Activation of the MAP kinase pathway by the protein kinase raf. Cell. 1992;71:335-342.
19. Kolch W, Heidecker G, Lloyd P, Rapp UR. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature. 1991;349:426-428.
20. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligonucleotide targeted against C-raf kinase. Nat Med. 1996;2: 668-675.
21. Kohl NE, Omer CA, Conner MW. Inhibition of farneyl-transferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1995;1:792-797.
22. ras promotes tumor regression. Cancer Res. 1998;58:1170-1176.
23. Katz ME, McCormick F. Signal transduction from multiple Ras effectors. Curr Opin Genet Dev. 1997;7:75-79.
24. Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene. 1998;17: 1415-1438.
25. Land H, Parada F, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983;304:596-602.
26. Leone G, DeGregori J, Sears R, Jakol L, Nevins JR. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 1997;87:422-426.
27. Lloyd AC, Obermuller F, Staddon S, Barth CF, McMahon M, Land H. Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. 1997;11:663-677.
28. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 1993;217:581-599.
29. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901-910.
30. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993;90:8392-8396.
31. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol. 1988;62:1120-1124.
32. Seliger B, Pfizenmaier K, Schaefer R. Short-term treatment with γ interferon induces stable reversion of ras-transformed mouse fibroblasts. J Virol. 1991;65:6307-6311.
33. Lovric J, Bischof O, Moelling K. Cell cycle-dependent association of Gag-Mil and hsp90. FEBS Lett. 1994;343: 15-21.
34. Vermes I, Haanen C, Steffens NH, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein-labeled annexin V. J Immunol Methods. 1995;184:39-51.
35. Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Science. 1993;260:85-88.
36. Qui RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature. 1995;374:457-459.
37. Koshravi-Far R, Solski PA, Clark GJ, Kinch MS, Der C. Activation of Rac1, RhoA, and mitogen-activated protein kinase is required for Ras transformation. Mol Cell Biol. 1995;15:6443-6453.
38. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene. 1998;17:1395-1413.
39. Rommel C, Hafen E. Ras: a versatile cellular switch. Curr Opin Genet Dev. 1998;8:412-418.
40. Clark GJ, Drugan JK, Terrell RS, et al. Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase-activating protein NF1 inhibit Ras function. Proc Natl Acad Sci USA. 1996;93:1577-1581.
41. Plattner R, Anderson MJ, Sato KY, Fasching CL, Der CJ, Stanbridge EJ. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc Natl Acad Sci USA. 1996;93:6665-6670.
42. Rapp UR, Troppmair J, Beck T, Birrer MJ. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant. Oncogene. 1994;9:3493-3498.
43. Silberman S, Janulis M, Schultz RM. Characterization of downstream Ras signals that induce alternative protease-dependent invasive phenotypes. J Biol Chem. 1997;272: 5927-5935.
44. Barone MV, Courtneidge SA. Myc but not Fos rescue of PDGF signaling block caused by kinase-inactive Src. Nature. 1995;378:509-512.